Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

• Ghulam Rehman Mohyuddin,
• Rajshekhar Chakraborty,
• Gregory S. Calip,
• Mustafa S. Ascha,
• Xiaoliang Wang,
• Samuel M. Rubinstein,
• Sascha Tuchman,
• Luciano Costa,
• Benjamin Haaland,
• Smith Giri,
• Hira Mian,
• Rafael Fonseca,
• Douglas Sborov

Affiliations

Ghulam Rehman Mohyuddin

Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah

Rajshekhar Chakraborty

Department of Hematology, Columbia University

Gregory S. Calip

Flatiron Health

Mustafa S. Ascha

Flatiron Health

Xiaoliang Wang

Flatiron Health

Samuel M. Rubinstein

Department of Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Sascha Tuchman

Department of Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Luciano Costa

Division of Hematology and Oncology, University of Alabama at Birmingham

Benjamin Haaland

Department of Population Sciences, University of Utah

Smith Giri

Division of Hematology and Oncology, University of Alabama at Birmingham

Hira Mian

Department of Oncology, McMaster University

Rafael Fonseca

Division of Hematology and Oncology, Mayo Clinic in Arizona

Douglas Sborov

Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah